BioCareSD Builds Depth in Specialty Distribution by Adding VYVGART HYTRULO to Therapies for Generalized Myasthenia Gravisadmin
TEMPE, Ariz. – July 19, 2023 – BioCareSD today announced VYVGART® HYTRULO injection for subcutaneous use in generalized myasthenia gravis (gMG) will join their fast-growing list of specialty products available for distribution. VYVGART HYTRULO is the first U.S. Food & Drug Administration (FDA) approved subcutaneous injectable for gMG in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
“As more and more therapies are FDA-approved, BioCare is at the forefront of early adoption of these instrumental treatments in specialty pharmaceuticals,” said Andrew Flessor, Senior Director of Business Development at BioCareSD. “We are dedicated to making sure that our healthcare partners in specialty pharmacies, hospitals, infusion centers and physicians’ offices are also at the forefront of medicine when delivering the safest, highest quality of care to their patients.”
VYVGART HYTRULO is for subcutaneous use only and administered with a winged infusion set by a healthcare professional. Recommended dosage is 1,008 mg / 11,200 units (1,008 mg efgartigimod alfa and 11,200 units hyaluronidase) over 30 to 90 seconds in cycles of once weekly injections for four weeks.
The availability of VYVGART HYTRULO as a gMG treatment option in subcutaneous delivery opens up opportunities for patients to receive treatment at home, in an infusion center, or at a physician’s office – an overall approach that puts the patient experience at the center of care delivery.
Over the last four decades, BioCareSD has delivered therapies to patients with ultra-rare, rare, and orphan diseases through partnerships with manufacturers and healthcare providers. For more information, please visit www.biocaresd.com.